JP2022526850A5 - - Google Patents
Info
- Publication number
- JP2022526850A5 JP2022526850A5 JP2021560255A JP2021560255A JP2022526850A5 JP 2022526850 A5 JP2022526850 A5 JP 2022526850A5 JP 2021560255 A JP2021560255 A JP 2021560255A JP 2021560255 A JP2021560255 A JP 2021560255A JP 2022526850 A5 JP2022526850 A5 JP 2022526850A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- hydrogen
- compound according
- aforementioned solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024210028A JP2025029094A (ja) | 2019-04-12 | 2024-12-03 | Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833529P | 2019-04-12 | 2019-04-12 | |
| US62/833,529 | 2019-04-12 | ||
| US201962911016P | 2019-10-04 | 2019-10-04 | |
| US62/911,016 | 2019-10-04 | ||
| US201962930240P | 2019-11-04 | 2019-11-04 | |
| US62/930,240 | 2019-11-04 | ||
| PCT/US2020/027177 WO2020210293A1 (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210028A Division JP2025029094A (ja) | 2019-04-12 | 2024-12-03 | Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526850A JP2022526850A (ja) | 2022-05-26 |
| JP2022526850A5 true JP2022526850A5 (enExample) | 2023-04-17 |
| JP7600140B2 JP7600140B2 (ja) | 2024-12-16 |
Family
ID=70416596
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560255A Active JP7600140B2 (ja) | 2019-04-12 | 2020-04-08 | Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法 |
| JP2024210028A Pending JP2025029094A (ja) | 2019-04-12 | 2024-12-03 | Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210028A Pending JP2025029094A (ja) | 2019-04-12 | 2024-12-03 | Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法 |
Country Status (33)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109970745B (zh) | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| SG11202111244XA (en) | 2019-04-12 | 2021-11-29 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
| CN117098760B (zh) * | 2020-10-14 | 2026-04-14 | 缆图药品公司 | 用于治疗kit和pdgfra介导的疾病的组合物和方法 |
| WO2022081626A1 (en) * | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| JP7763848B2 (ja) * | 2021-03-03 | 2025-11-04 | ブループリント メディシンズ コーポレイション | Ｋｉｔ－およびｐｄｇｆｒａ－媒介性疾患を治療するための化合物を製造するための合成方法および中間生成物 |
| WO2022192558A1 (en) | 2021-03-10 | 2022-09-15 | Blueprint Medicines Corporation | Salt and solid forms of a kinase inhibitor |
| CN117794935A (zh) * | 2021-03-10 | 2024-03-29 | 缆图药品公司 | 激酶抑制剂的盐和固体形式 |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| US20250129067A1 (en) * | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2024171143A1 (en) | 2023-02-17 | 2024-08-22 | Assia Chemical Industries Ltd. | Salts and solid forms of elenestinib |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| IL144977A0 (en) * | 1999-05-21 | 2002-06-30 | Bristol Myers Squibb Co | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| PL219736B1 (pl) | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1755607A2 (en) | 2004-04-29 | 2007-02-28 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PL1973910T3 (pl) | 2006-01-27 | 2013-11-29 | Shanghai hengrui pharmaceutical co ltd | Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej |
| SI2041138T1 (sl) | 2006-07-07 | 2014-08-29 | Bristol-Myers Squibb Company | Pirolotriazin kinazni inhibitorji |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| AU2009226024B2 (en) | 2008-03-20 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| CA2764818A1 (en) | 2009-06-08 | 2010-12-16 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| AU2011218167B2 (en) | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| WO2013004551A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| KR102398659B1 (ko) | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| CN109970745B (zh) | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| CR20200588A (es) | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| WO2020102095A1 (en) | 2018-11-12 | 2020-05-22 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| PE20211756A1 (es) | 2018-12-20 | 2021-09-07 | Pfizer | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß |
| SG11202111244XA (en) | 2019-04-12 | 2021-11-29 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| WO2022081626A1 (en) | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
-
2020
- 2020-04-08 SG SG11202111244XA patent/SG11202111244XA/en unknown
- 2020-04-08 MX MX2021012469A patent/MX2021012469A/es unknown
- 2020-04-08 MA MA55604A patent/MA55604B1/fr unknown
- 2020-04-08 EP EP24170331.3A patent/EP4424312A3/en active Pending
- 2020-04-08 MY MYPI2021006079A patent/MY209048A/en unknown
- 2020-04-08 HU HUE20721083A patent/HUE067299T2/hu unknown
- 2020-04-08 LT LTEPPCT/US2020/027177T patent/LT3953357T/lt unknown
- 2020-04-08 PE PE2021001699A patent/PE20212331A1/es unknown
- 2020-04-08 HR HRP20240702TT patent/HRP20240702T1/hr unknown
- 2020-04-08 SM SM20240229T patent/SMT202400229T1/it unknown
- 2020-04-08 US US17/602,770 patent/US12552795B2/en active Active
- 2020-04-08 SI SI202030454T patent/SI3953357T1/sl unknown
- 2020-04-08 JP JP2021560255A patent/JP7600140B2/ja active Active
- 2020-04-08 IL IL287168A patent/IL287168B2/en unknown
- 2020-04-08 ES ES20721083T patent/ES2980811T3/es active Active
- 2020-04-08 US US16/842,969 patent/US10829493B2/en active Active
- 2020-04-08 CA CA3136802A patent/CA3136802A1/en active Pending
- 2020-04-08 BR BR112021020441A patent/BR112021020441A2/pt unknown
- 2020-04-08 TW TW109111858A patent/TWI857043B/zh active
- 2020-04-08 DK DK20721083.2T patent/DK3953357T3/da active
- 2020-04-08 MD MDE20220189T patent/MD3953357T2/ro unknown
- 2020-04-08 FI FIEP20721083.2T patent/FI3953357T3/fi active
- 2020-04-08 PT PT207210832T patent/PT3953357T/pt unknown
- 2020-04-08 PL PL20721083.2T patent/PL3953357T3/pl unknown
- 2020-04-08 AU AU2020272743A patent/AU2020272743B2/en active Active
- 2020-04-08 WO PCT/US2020/027177 patent/WO2020210293A1/en not_active Ceased
- 2020-04-08 EP EP20721083.2A patent/EP3953357B1/en active Active
- 2020-04-08 KR KR1020217036868A patent/KR102875260B1/ko active Active
- 2020-04-08 RS RS20240664A patent/RS65644B1/sr unknown
- 2020-04-08 CN CN202080042732.0A patent/CN113939515B/zh active Active
-
2021
- 2021-04-08 PH PH1/2021/552568A patent/PH12021552568A1/en unknown
- 2021-10-12 CL CL2021002656A patent/CL2021002656A1/es unknown
- 2021-10-21 ZA ZA2021/08104A patent/ZA202108104B/en unknown
- 2021-11-09 CO CONC2021/0015113A patent/CO2021015113A2/es unknown
- 2021-11-12 EC ECSENADI202180096A patent/ECSP21080096A/es unknown
-
2024
- 2024-12-03 JP JP2024210028A patent/JP2025029094A/ja active Pending
-
2026
- 2026-01-22 US US19/456,134 patent/US20260138986A1/en active Pending